This study reveals the dual role of epithelium-derived APRIL in regulating colonic epithelial homeostasis and B cell function, providing a novel experimental paradigm for investigating epithelial-immune crosstalk in inflammatory bowel disease, suggesting that targeting the FAS signaling axis may have clinical intervention potential.
Literature Overview
The study, 'TNFSF13 insufficiency disrupts human colonic epithelial cell growth and associated B cell dynamics,' published in The Journal of Clinical Investigation, systematically investigates how a novel APRIL (TNFSF13) gene variant affects the balance between proliferation and apoptosis in colonic epithelial cells and mediates epithelial-immune crosstalk in the context of very-early-onset inflammatory bowel disease (VEO-IBD). By integrating patient-derived tissue organoids and iPSC-derived organoid models, the study deeply elucidates the non-canonical functions of APRIL in epithelial-autonomous regulation and B cell differentiation, expanding our understanding of the pathogenesis of inflammatory bowel disease.Background Knowledge
1. The clinical challenge of inflammatory bowel disease addressed by this study: VEO-IBD in children often presents with more severe clinical phenotypes, treatment resistance, and genetic heterogeneity. Traditional immune-centered therapeutic strategies are frequently ineffective, indicating that epithelial barrier dysfunction and disrupted epithelial-immune crosstalk are key pathological components. Currently, there is a lack of targeted therapies aimed at restoring epithelial function.
2. Current research bottlenecks for APRIL: APRIL has traditionally been regarded as a key factor in B cell maturation and antibody secretion, primarily secreted by myeloid cells, while its function in epithelial cells has long been overlooked. Although some studies suggest epithelial cells can secrete APRIL, its receptors, signaling pathways, and specific mechanisms in intestinal homeostasis remain unclear.
3. Research rationale: The authors identified a novel heterozygous APRIL frameshift mutation in a patient with severe infantile colitis via whole-exome sequencing. Using patient-derived colonic organoids and iPSC-derived organoid models, they systematically analyzed the functional consequences of this mutation. Their findings reveal a non-immunological role of epithelium-derived APRIL in regulating epithelial proliferation and B cell differentiation through the FAS receptor, offering new insights for epithelium-targeted therapies in inflammatory bowel disease.
Research Methods and Experiments
The authors first identified a de novo heterozygous APRIL frameshift mutation (c.372_373insT) in a VEO-IBD patient diagnosed at 4 months of age using whole-exome sequencing. This mutation leads to premature protein termination, predicting a significant reduction in secreted APRIL. Using colonic organoids derived from patient biopsy tissues, combined with ELISA and RNAscope validation, the study confirmed significantly reduced APRIL expression. To exclude interference from the tissue microenvironment, the authors further generated iPSC-derived colonic organoids carrying the same mutation, which recapitulated the phenotypes of reduced APRIL expression and increased organoid number and size, confirming epithelial-autonomous effects.
Using single-cell RNA sequencing (scRNA-seq) and flow cytometry, the authors found that colonic epithelial cells do not express the canonical APRIL receptors TACI or BCMA, but instead express FAS and HVEM. Co-immunoprecipitation (Co-IP), surface plasmon resonance (SPR), and molecular docking simulations confirmed that APRIL can directly bind FAS, albeit with lower affinity than FASL. Functional experiments showed that neutralizing APRIL or FAS promotes epithelial proliferation, while exogenous APRIL rescues the hyperproliferative phenotype in mutant organoids, indicating that the APRIL-FAS axis negatively regulates epithelial proliferation.
At the immune level, imaging mass cytometry (IMC) and scRNA-seq analyses revealed increased B cell clustering but reduced IgA+ plasma cells in the colonic tissues of patients with the APRIL mutation. The authors established an organoid-memory B cell co-culture system and found that conditioned medium from mutant organoids significantly reduced the differentiation efficiency of plasma cells and IgA+ plasma cells. Further experiments showed that neutralizing FAS antibody enhances memory B cell differentiation into plasma cells, and this effect is dependent on APRIL, revealing a novel mechanism by which epithelium-derived APRIL regulates B cell fate via FAS.Key Conclusions and Perspectives
Research Significance and Prospects
This study, starting from a clinical mutation and validated through multiple models, establishes a new role for epithelium-derived APRIL as a dual regulator of colonic epithelial homeostasis and B cell differentiation. It provides a new molecular explanation for the heterogeneity of inflammatory bowel disease, particularly in cases resistant to immunosuppressive therapy, which may be linked to epithelial-autonomous APRIL deficiency.
From a drug development perspective, enhancing APRIL-FAS signaling may help restore epithelial barrier integrity and mucosal immune balance, representing a therapeutic strategy distinct from conventional immunosuppression. Furthermore, the iPSC-derived organoid and B cell co-culture platform established in this study provides a powerful tool for future high-throughput drug screening and personalized therapy testing.
In terms of clinical monitoring, assessing epithelial APRIL expression levels or serum biomarkers in patients may help stratify VEO-IBD individuals and identify subpopulations with potential epithelial dysfunction. Additionally, this study suggests that long-term use of anti-APRIL therapies (such as those used for IgA nephropathy) may impair intestinal epithelial repair, warranting clinical monitoring.
Conclusion
This study systematically reveals the non-canonical functions of APRIL in colonic epithelial cells by integrating patient genetics, organoid models, and epithelial-immune co-culture systems. It demonstrates that epithelium-derived APRIL negatively regulates epithelial proliferation and promotes memory B cell differentiation into plasma cells via the FAS receptor. Loss of this function leads to epithelial hyperproliferation and impaired B cell differentiation, collectively disrupting mucosal homeostasis. These findings not only deepen our understanding of the pathogenesis of inflammatory bowel disease, especially the genetic basis of early-onset cases, but also propose a novel therapeutic concept of 'epithelium-targeted repair.' From bench to bedside, this study provides a solid foundation for developing new therapies based on enhancing APRIL-FAS signaling and emphasizes the importance of considering epithelial-immune crosstalk in drug development. In the future, biomarker development based on this mechanism and the application of personalized organoid co-culture platforms are expected to significantly improve precision medicine for inflammatory bowel disease patients and reshape disease care systems.
